Results of a recent study may change the standard of care for patients with acute coronary syndromes. Although clopidogrel is generally the antiplatelet therapy of choice for patients for whom an invasive strategy is planned for treating their acute coronary syndromes, bleeding can be of concern. Prasugrel often presents the same dilemma. Enter, ticagrelor. The PLATelet inhibition and patient Outcomes, or PLATO, trial compared ticagrelor and clopidogrel, which demonstrated promising results for ticagrelor. Dr. Gregg Stone, professor of medicine and director of research and education at the Center for Interventional Vascular Therapy at the Columbia University Medical Center, and director of medical research and education at the Cardiovascular Research Foundation in New York City, hails the PLATO findings as transformative to the standard of care for acute coronary syndromes. He joins host Dr. Alfred Bove to discuss the new place of ticagrelor among the antiplatelet therapy options.
